Counselors in Worland, WY Accepting Medicare

24 Counselors found. Showing 1 - 20

Mrs. Deborah J Anderson, BA PSYCHOLOGY Counselor Medicare: Not Enrolled in Medicare Practice Location: 401 South 23rd St, Worland, WY 82401 Phone: 307-347-6165    Fax: 307-347-6166

Timothy Warren, MS, LPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 801 Robertson Ave, Worland, WY 82401 Phone: 402-707-7924    Fax: 402-707-7924

Kathleen D Smith, MA, MSW, LPC Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 1023 N Road 11, Worland, WY 82401 Phone: 307-347-2077

Gordon L Roupe, BSW, CMHW Counselor Medicare: Not Enrolled in Medicare Practice Location: 401 S 23rd St, Worland, WY 82401 Phone: 307-347-6165    Fax: 307-347-6166

Linda B Brandt, LPC, LAT Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 401 S 23rd St, Worland, WY 82401 Phone: 307-347-6165    Fax: 307-347-6165

Ms. Erin C Morgan, LPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 401 S 23rd St, Worland, WY 82401 Phone: 307-347-6165    Fax: 307-347-6166

Dale Adam Weber, M.S., LPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 401 S 23rd St, Worland, WY 82401 Phone: 307-347-6165    Fax: 307-347-6166

Lynn Fritzler, BS Counselor - Mental Health Medicare: Medicare Enrolled Practice Location: 401 S 23rd St, Worland, WY 82401 Phone: 307-347-6165    Fax: 307-347-6166

Megan Galovich Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 401 S 23rd St, Worland, WY 82401 Phone: 307-347-6165    Fax: 307-347-6166

Lonnie G Gerharter, M.ED., LAT Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 206 S 7th St, Worland, WY 82401 Phone: 307-347-6165    Fax: 307-347-6166

Mr. Jeffery D Pharaoh, MDIV MSW RMHC Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 401 S 23rd St, Worland, WY 82401 Phone: 307-347-6165    Fax: 307-347-6166

Jacqueline Mccoughlan, M.ED., LPC Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 206 S 7th St, Worland, WY 82401 Phone: 307-347-6165    Fax: 307-347-6166

Danielle Warren Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 801 Robertson Ave, Worland, WY 82401 Phone: 307-388-8591

Ms. Marlene Carol Paquin, M.S., L.P.C. Counselor - Mental Health Medicare: Medicare Enrolled Practice Location: 401 S 23rd St, Worland, WY 82401 Phone: 307-347-6165    Fax: 307-347-6166

Wendy K Wiecki, BA, CMHW Counselor Medicare: Not Enrolled in Medicare Practice Location: 401 S 23rd St, Worland, WY 82401 Phone: 307-347-6165    Fax: 307-347-6166

Mrs. Fee Rocha Counselor Medicare: Not Enrolled in Medicare Practice Location: 401 S 23rd St, Worland, WY 82401 Phone: 307-347-6165    Fax: 307-347-6165

Mrs. Andrea Kay Dannar, LPC Counselor Medicare: Medicare Enrolled Practice Location: 401 S 23rd St, Worland, WY 82401 Phone: 307-347-6165    Fax: 307-347-6166

Mrs. Kimberly R Accurso, LPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 735 Big Horn Ave, Worland, WY 82401 Phone: 307-431-1178

Janae B Harman, M.COUN., PPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 120 S 17th St, Worland, WY 82401 Phone: 307-347-4001

Mrs. Rebecca Jean Luhm, LCSW, M. ED Counselor - School Medicare: Not Enrolled in Medicare Practice Location: 601 S 15th St, Worland, WY 82401 Phone: 307-347-2366    Fax: 307-347-8259

News Archive

Benzodiazepines heighten risks for dementia and death

Patients taking benzodiazepines to treat psychiatric conditions should consider transitioning to other therapies because of heightened risks for dementia and death, according to clinicians from the American College of Osteopathic Neurologists and Psychiatrists.

Protox' Phase 2 study of PRX302 for treating BPH provides positive results

Protox Therapeutics Inc. (TSX: PRX), a leader in the development of receptor targeted fusion proteins, today announced positive 12 month data from its open-label Phase 2 study of PRX302 in males with moderate to severe benign prostatic hyperplasia (BPH). The study results indicate that those patients who received an optimal dose of PRX302 continued to demonstrate significant symptomatic relief at 12 months following a single treatment.

JHP Pharmaceuticals completes successful GMP/Pre Approval Audit by FDA CDER

JHP Pharmaceuticals' sterile manufacturing site based in Rochester, Michigan completed a successful GMP (Good Manufacturing Practices)/Pre Approval Audit by the U.S. Food and Drug Administration (FDA) drug division (CDER).

Scientists unravel the mystery behind ovarian cancer with high-grade serous carcinoma

More than two-thirds of women with ovarian cancer have high-grade serous carcinoma. Up to 90 percent of HGSCs are not detected until they are beyond the ovaries or fallopian tubes, at which point it may not be possible to fully remove the tumor.

Neuralstem files NSI-189 IND with FDA for Phase I safety trials for major depression

Neuralstem, Inc. announced that it has filed an Investigational New Drug (IND) application with the United States Food and Drug Administration (FDA) to begin two Phase I safety trials to test NSI-189, its first small molecule compound, for the treatment of major depression. NSI-189 is a proprietary new chemical entity discovered by Neuralstem that stimulates new neuron growth in the hippocampus, an area of the brain that is believed to be involved in depression.

Read more Medical News

› Verified 6 days ago

• 1(current)
• 2